JP2024511389A5 - - Google Patents
Info
- Publication number
- JP2024511389A5 JP2024511389A5 JP2023557142A JP2023557142A JP2024511389A5 JP 2024511389 A5 JP2024511389 A5 JP 2024511389A5 JP 2023557142 A JP2023557142 A JP 2023557142A JP 2023557142 A JP2023557142 A JP 2023557142A JP 2024511389 A5 JP2024511389 A5 JP 2024511389A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- groups
- pharmaceutical composition
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110316525.6 | 2021-03-24 | ||
| CN202110316525 | 2021-03-24 | ||
| CN2022074619 | 2022-01-28 | ||
| CN202210109766.8 | 2022-01-28 | ||
| CNPCT/CN2022/074619 | 2022-01-28 | ||
| CN202210109766 | 2022-01-28 | ||
| PCT/CN2022/081890 WO2022199503A1 (zh) | 2021-03-24 | 2022-03-21 | 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511389A JP2024511389A (ja) | 2024-03-13 |
| JP2024511389A5 true JP2024511389A5 (enExample) | 2025-03-25 |
Family
ID=83396096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557142A Pending JP2024511389A (ja) | 2021-03-24 | 2022-03-21 | キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250268897A1 (enExample) |
| EP (1) | EP4316490A4 (enExample) |
| JP (1) | JP2024511389A (enExample) |
| KR (1) | KR20230159367A (enExample) |
| CN (1) | CN116801882A (enExample) |
| AU (1) | AU2022242476A1 (enExample) |
| WO (1) | WO2022199503A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7688690B2 (ja) * | 2020-07-28 | 2025-06-04 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | ピリミジン系化合物の塩、結晶形およびその調製方法 |
| CN120897743A (zh) | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) * | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012154518A1 (en) * | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| WO2018017983A1 (en) * | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| TWI791053B (zh) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| EP3740491A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2020114474A1 (zh) * | 2018-12-06 | 2020-06-11 | 苏州信诺维医药科技有限公司 | 一种杂环化合物、其应用及含其的药物组合物 |
| JP7615056B2 (ja) | 2019-02-19 | 2025-01-16 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 複素環化合物、これを含む薬物組成物、その製造方法および使用 |
| MX2021014273A (es) * | 2019-05-21 | 2022-01-06 | Voronoi Inc | Derivado de heteroarilo que contiene n y composicion farmaceutica que lo comprende como principio activo para la prevencion o el tratamiento de cancer. |
| CN113490670B (zh) * | 2019-08-05 | 2023-06-02 | 北京志健金瑞生物医药科技有限公司 | 含氮多环稠环类化合物,其药物组合物、制备方法和用途 |
-
2022
- 2022-03-21 WO PCT/CN2022/081890 patent/WO2022199503A1/zh not_active Ceased
- 2022-03-21 CN CN202280011390.5A patent/CN116801882A/zh active Pending
- 2022-03-21 AU AU2022242476A patent/AU2022242476A1/en active Pending
- 2022-03-21 KR KR1020237025273A patent/KR20230159367A/ko active Pending
- 2022-03-21 EP EP22774164.2A patent/EP4316490A4/en active Pending
- 2022-03-21 JP JP2023557142A patent/JP2024511389A/ja active Pending
- 2022-03-21 US US18/283,673 patent/US20250268897A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022138987A5 (enExample) | ||
| AU2007336781C1 (en) | Pyridazinones and furan-containing compounds | |
| US6734203B2 (en) | Fused imidazolium derivatives | |
| IL268030B2 (en) | Bicyclics as allosteric shp2 inhibitors | |
| JP2022520448A5 (enExample) | ||
| JP2020508311A (ja) | アリール炭化水素受容体（ＡｈＲ）モジュレーター化合物 | |
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| AU2016327857B2 (en) | EGFR kinase inhibitor and preparation method and use thereof | |
| WO2019012172A1 (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) | |
| WO2021016333A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| JP2023526791A5 (enExample) | ||
| JP2018529690A5 (enExample) | ||
| CN107698603A (zh) | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 | |
| WO2022166592A1 (zh) | 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用 | |
| JP2025120182A5 (enExample) | ||
| JP2022521859A5 (enExample) | ||
| JP2018529643A5 (enExample) | ||
| CN109790145A (zh) | 二氢嘧啶类化合物及其制备方法和用途 | |
| US9738613B2 (en) | Substituted 1,2,3-triazoles as antitumor agents | |
| CN112174950A (zh) | 杂环衍生物、包含其的药物组合物及其用途 | |
| JPWO2021117759A5 (enExample) | ||
| CN111295387B (zh) | 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用 | |
| CN111718349A (zh) | 含氟吡唑并嘧啶化合物和药物组合物及其应用 | |
| EP3628374B1 (en) | Bcl-3 inhibitors | |
| JPWO2022145408A5 (enExample) |